Nucleos(t)ide analogue treatment for patients with hepatiThis B virus (HBV) e antigen-positive chronic HBV genotype C infection: A Nationwide, Multicenter, Retrospective Study

Young Chang, Won Hyeok Choe, Dong Hyun Sinn, Jeong Hoon Lee, SangHoon Ahn, Hyewon Lee, Jae Jun Shim, Dae Won Jun, Soo Young Park, Joon Yeul Nam, Eun Ju Cho, Su Jong Yu, Dong Ho Lee, Jeong Min Lee, Yoon Jun Kim, So Young Kwon, Seung Woon Paik, Jung Hwan Yoon

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background. Antiviral treatment for hepatiThis B virus (HBV) e antigen (HBeAg)-positive chronic HBV infection is still controversial. We assessed whether antiviral treatment reduces the risk of liver disease progression in these patients. Methods. This study included consecutive patients in 8 large-volume hospitals in Korea who tested positive for HBeAg and had an HBV DNA level of >20 000 IU/mL, an alanine aminotransferase (ALT) level of <40 IU/L, and no evidence of cirrhosis. Te primary end point was the development of hepatocellular carcinoma (HCC), and the secondary end point was the development of cirrhosis. Results. A total of 484 patients were included: 87 were in the antiviral treatment group, and 397 were in the control group. Baseline liver function was signifcantly more favorable for the control group. Afer matching for propensity score to overcome those di?erences, the antiviral treatment group had a signifcantly reduced risk for HCC (hazard ratio [HR], 0.234; log-rank P =.046) and cirrhosis (HR, 0.235; log-rank P =.015), compared with the control group. Afer balancing the baseline characteristics by using inverse probability weighting, antiviral therapy signifcantly decreased the risk of HCC (HR, 0.189; log-rank P =.004) and cirrhosis (HR, 0.347; log-rank P =.036). Conclusion. Antiviral therapy for patients with HBeAg-positive chronic HBV infection and have a high HBV load reduces the risk of HCC, even if the ALT level is below the upper limit of normal.

Original languageEnglish
Pages (from-to)1407-1414
Number of pages8
JournalJournal of Infectious Diseases
Volume216
Issue number11
DOIs
Publication statusPublished - 2017 Dec 1

Fingerprint

Cercopithecine Herpesvirus 1
Hepatitis B e Antigens
Multicenter Studies
Antiviral Agents
Retrospective Studies
Genotype
Hepatocellular Carcinoma
Fibrosis
Infection
Virus Diseases
Alanine Transaminase
Control Groups
Therapeutics
Propensity Score
Korea
Disease Progression
Liver Diseases
Liver
DNA

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Chang, Young ; Choe, Won Hyeok ; Sinn, Dong Hyun ; Lee, Jeong Hoon ; Ahn, SangHoon ; Lee, Hyewon ; Shim, Jae Jun ; Jun, Dae Won ; Park, Soo Young ; Nam, Joon Yeul ; Cho, Eun Ju ; Yu, Su Jong ; Lee, Dong Ho ; Lee, Jeong Min ; Kim, Yoon Jun ; Kwon, So Young ; Paik, Seung Woon ; Yoon, Jung Hwan. / Nucleos(t)ide analogue treatment for patients with hepatiThis B virus (HBV) e antigen-positive chronic HBV genotype C infection : A Nationwide, Multicenter, Retrospective Study. In: Journal of Infectious Diseases. 2017 ; Vol. 216, No. 11. pp. 1407-1414.
@article{84c88ac735af48cf8bedde4216f9471c,
title = "Nucleos(t)ide analogue treatment for patients with hepatiThis B virus (HBV) e antigen-positive chronic HBV genotype C infection: A Nationwide, Multicenter, Retrospective Study",
abstract = "Background. Antiviral treatment for hepatiThis B virus (HBV) e antigen (HBeAg)-positive chronic HBV infection is still controversial. We assessed whether antiviral treatment reduces the risk of liver disease progression in these patients. Methods. This study included consecutive patients in 8 large-volume hospitals in Korea who tested positive for HBeAg and had an HBV DNA level of >20 000 IU/mL, an alanine aminotransferase (ALT) level of <40 IU/L, and no evidence of cirrhosis. Te primary end point was the development of hepatocellular carcinoma (HCC), and the secondary end point was the development of cirrhosis. Results. A total of 484 patients were included: 87 were in the antiviral treatment group, and 397 were in the control group. Baseline liver function was signifcantly more favorable for the control group. Afer matching for propensity score to overcome those di?erences, the antiviral treatment group had a signifcantly reduced risk for HCC (hazard ratio [HR], 0.234; log-rank P =.046) and cirrhosis (HR, 0.235; log-rank P =.015), compared with the control group. Afer balancing the baseline characteristics by using inverse probability weighting, antiviral therapy signifcantly decreased the risk of HCC (HR, 0.189; log-rank P =.004) and cirrhosis (HR, 0.347; log-rank P =.036). Conclusion. Antiviral therapy for patients with HBeAg-positive chronic HBV infection and have a high HBV load reduces the risk of HCC, even if the ALT level is below the upper limit of normal.",
author = "Young Chang and Choe, {Won Hyeok} and Sinn, {Dong Hyun} and Lee, {Jeong Hoon} and SangHoon Ahn and Hyewon Lee and Shim, {Jae Jun} and Jun, {Dae Won} and Park, {Soo Young} and Nam, {Joon Yeul} and Cho, {Eun Ju} and Yu, {Su Jong} and Lee, {Dong Ho} and Lee, {Jeong Min} and Kim, {Yoon Jun} and Kwon, {So Young} and Paik, {Seung Woon} and Yoon, {Jung Hwan}",
year = "2017",
month = "12",
day = "1",
doi = "10.1093/infdis/jix506",
language = "English",
volume = "216",
pages = "1407--1414",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "11",

}

Chang, Y, Choe, WH, Sinn, DH, Lee, JH, Ahn, S, Lee, H, Shim, JJ, Jun, DW, Park, SY, Nam, JY, Cho, EJ, Yu, SJ, Lee, DH, Lee, JM, Kim, YJ, Kwon, SY, Paik, SW & Yoon, JH 2017, 'Nucleos(t)ide analogue treatment for patients with hepatiThis B virus (HBV) e antigen-positive chronic HBV genotype C infection: A Nationwide, Multicenter, Retrospective Study', Journal of Infectious Diseases, vol. 216, no. 11, pp. 1407-1414. https://doi.org/10.1093/infdis/jix506

Nucleos(t)ide analogue treatment for patients with hepatiThis B virus (HBV) e antigen-positive chronic HBV genotype C infection : A Nationwide, Multicenter, Retrospective Study. / Chang, Young; Choe, Won Hyeok; Sinn, Dong Hyun; Lee, Jeong Hoon; Ahn, SangHoon; Lee, Hyewon; Shim, Jae Jun; Jun, Dae Won; Park, Soo Young; Nam, Joon Yeul; Cho, Eun Ju; Yu, Su Jong; Lee, Dong Ho; Lee, Jeong Min; Kim, Yoon Jun; Kwon, So Young; Paik, Seung Woon; Yoon, Jung Hwan.

In: Journal of Infectious Diseases, Vol. 216, No. 11, 01.12.2017, p. 1407-1414.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Nucleos(t)ide analogue treatment for patients with hepatiThis B virus (HBV) e antigen-positive chronic HBV genotype C infection

T2 - A Nationwide, Multicenter, Retrospective Study

AU - Chang, Young

AU - Choe, Won Hyeok

AU - Sinn, Dong Hyun

AU - Lee, Jeong Hoon

AU - Ahn, SangHoon

AU - Lee, Hyewon

AU - Shim, Jae Jun

AU - Jun, Dae Won

AU - Park, Soo Young

AU - Nam, Joon Yeul

AU - Cho, Eun Ju

AU - Yu, Su Jong

AU - Lee, Dong Ho

AU - Lee, Jeong Min

AU - Kim, Yoon Jun

AU - Kwon, So Young

AU - Paik, Seung Woon

AU - Yoon, Jung Hwan

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Background. Antiviral treatment for hepatiThis B virus (HBV) e antigen (HBeAg)-positive chronic HBV infection is still controversial. We assessed whether antiviral treatment reduces the risk of liver disease progression in these patients. Methods. This study included consecutive patients in 8 large-volume hospitals in Korea who tested positive for HBeAg and had an HBV DNA level of >20 000 IU/mL, an alanine aminotransferase (ALT) level of <40 IU/L, and no evidence of cirrhosis. Te primary end point was the development of hepatocellular carcinoma (HCC), and the secondary end point was the development of cirrhosis. Results. A total of 484 patients were included: 87 were in the antiviral treatment group, and 397 were in the control group. Baseline liver function was signifcantly more favorable for the control group. Afer matching for propensity score to overcome those di?erences, the antiviral treatment group had a signifcantly reduced risk for HCC (hazard ratio [HR], 0.234; log-rank P =.046) and cirrhosis (HR, 0.235; log-rank P =.015), compared with the control group. Afer balancing the baseline characteristics by using inverse probability weighting, antiviral therapy signifcantly decreased the risk of HCC (HR, 0.189; log-rank P =.004) and cirrhosis (HR, 0.347; log-rank P =.036). Conclusion. Antiviral therapy for patients with HBeAg-positive chronic HBV infection and have a high HBV load reduces the risk of HCC, even if the ALT level is below the upper limit of normal.

AB - Background. Antiviral treatment for hepatiThis B virus (HBV) e antigen (HBeAg)-positive chronic HBV infection is still controversial. We assessed whether antiviral treatment reduces the risk of liver disease progression in these patients. Methods. This study included consecutive patients in 8 large-volume hospitals in Korea who tested positive for HBeAg and had an HBV DNA level of >20 000 IU/mL, an alanine aminotransferase (ALT) level of <40 IU/L, and no evidence of cirrhosis. Te primary end point was the development of hepatocellular carcinoma (HCC), and the secondary end point was the development of cirrhosis. Results. A total of 484 patients were included: 87 were in the antiviral treatment group, and 397 were in the control group. Baseline liver function was signifcantly more favorable for the control group. Afer matching for propensity score to overcome those di?erences, the antiviral treatment group had a signifcantly reduced risk for HCC (hazard ratio [HR], 0.234; log-rank P =.046) and cirrhosis (HR, 0.235; log-rank P =.015), compared with the control group. Afer balancing the baseline characteristics by using inverse probability weighting, antiviral therapy signifcantly decreased the risk of HCC (HR, 0.189; log-rank P =.004) and cirrhosis (HR, 0.347; log-rank P =.036). Conclusion. Antiviral therapy for patients with HBeAg-positive chronic HBV infection and have a high HBV load reduces the risk of HCC, even if the ALT level is below the upper limit of normal.

UR - http://www.scopus.com/inward/record.url?scp=85038641366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038641366&partnerID=8YFLogxK

U2 - 10.1093/infdis/jix506

DO - 10.1093/infdis/jix506

M3 - Article

C2 - 29029102

AN - SCOPUS:85038641366

VL - 216

SP - 1407

EP - 1414

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 11

ER -